Helen Pentikis
Gründer bei Zero Point Five Therapeutics, Inc.
Profil
Helen S.
Pentikis is the founder and Chief Executive Officer & Chief Scientific Officer of SAJE Pharma LLC since 2011.
She is also the founder of Zero Point Five Therapeutics, Inc., GSNO Therapeutics, Inc. Helen's current job is Chief Scientific Officer at Symbiomix Therapeutics LLC.
Her former job was Chief Scientific Officer at Processa Pharmaceuticals, Inc. Helen received her undergraduate degree from Wake Forest University and her doctorate from the University of Maryland.
Aktive Positionen von Helen Pentikis
| Unternehmen | Position | Beginn |
|---|---|---|
Symbiomix Therapeutics LLC
 Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
SAJE Pharma LLC
 SAJE Pharma LLC Pharmaceuticals: MajorHealth Technology SAJE Pharma LLC operates as a biopharmaceutical company. It focuses on developing new therapeutic agents that provide significant benefits over available therapies for rare and common diseases with unmet medical needs. The company was founded by Matthews O. Bradley and Helen S. Pentikis in 2011 and is headquartered in Baltimore, MD. | Vorstandsvorsitzender | 01.01.2011 |
Zero Point Five Therapeutics, Inc.
 Zero Point Five Therapeutics, Inc. BiotechnologyHealth Technology Zero Point Five Therapeutics, Inc. is a drug development company that focuses on neglected tropical diseases and soil-transmitted helminthiasis. The company is based in Baltimore, MD. The company was founded by Helen S. Pentikis, Joseph L. Amprey. Joseph L. Amprey has been the CEO since incorporation. | Gründer | - |
Ehemalige bekannte Positionen von Helen Pentikis
| Unternehmen | Position | Ende |
|---|---|---|
| PROCESSA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Helen Pentikis
| Wake Forest University | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PROCESSA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
SAJE Pharma LLC
SAJE Pharma LLC Pharmaceuticals: MajorHealth Technology SAJE Pharma LLC operates as a biopharmaceutical company. It focuses on developing new therapeutic agents that provide significant benefits over available therapies for rare and common diseases with unmet medical needs. The company was founded by Matthews O. Bradley and Helen S. Pentikis in 2011 and is headquartered in Baltimore, MD. | Health Technology |
Symbiomix Therapeutics LLC
Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Health Technology |
Zero Point Five Therapeutics, Inc.
Zero Point Five Therapeutics, Inc. BiotechnologyHealth Technology Zero Point Five Therapeutics, Inc. is a drug development company that focuses on neglected tropical diseases and soil-transmitted helminthiasis. The company is based in Baltimore, MD. The company was founded by Helen S. Pentikis, Joseph L. Amprey. Joseph L. Amprey has been the CEO since incorporation. | Health Technology |
